Novo Nordisk released first quarter results on May 6, 2026, adjusting its 2026 sales guidance from down 5-13% to down 4-12%. The improved outlook follows a hugely successful U.S. launch of an oral Wegovy pill, helping Novo Nordisk gain momentum against rival Eli Lilly in the obesity drug market after previously trailing in the space.
Novo Nordisk earnings results
- ▪Vivek Ramaswamy won the Republican primary for governor of Ohio on May 5, 2026
- ▪Novo Nordisk adjusted its 2026 guidance to forecast adjusted sales will drop from 4% to 12%, compared to a previous forecast of down 5% to 13%
- ▪Novo Nordisk's improving outlook is largely driven by better sales performance
- ▪Novo Nordisk released first quarter results on May 6, 2026
- ▪Novo Nordisk adjusted its 2026 forecast for adjusted operating profit with an identical shift to its sales guidance
Wegovy oral formulation progress
- ▪Novo Nordisk launched a Wegovy pill in the U.S.
- ▪Novo Nordisk's Wegovy pill launch in the U.S. was hugely successful
- ▪Novo Nordisk had been trailing rival Eli Lilly in the obesity drug market
- ▪Novo Nordisk has gained recent momentum in the obesity drug market
Industry earnings roundup
- ▪United Therapeutics reported earnings
- ▪Madrigal Pharma's Rezdiffra first quarter 2026 sales topped Wall Street estimates
- ▪Madrigal Pharma reported sales of its MASH drug Rezdiffra were $311 million in the first quarter of 2026
Bayer acquisition activity
- ▪Bayer is acquiring Perfusion Therapeutics
- ▪Perfusion Therapeutics is a privately held developer of treatments for eye diseases
Story comments
Loading comments…